论文部分内容阅读
作者报告治疗重症再生障碍性贫血(再障)53例,其中3例入院时已处于晚期,未接受特殊治疗即死亡。其余50例分为3组。3组的年龄、病因、既往治疗情况、血象及输血史大致相似。A组:18例,输入组织相容性抗原 HLA-A,B,Dr 相同的同胞兄弟骨髓,其混合淋巴细胞培养无反应。平均输入3.75×10~3个骨髓有核细胞/kg。输前均给4次环磷酰胺,每次50mg/kg。有7例存在主要的 ABO 屏障而需更换血浆。最初7例只给予骨髓,其余11例在骨髓移植后5天,每天输入由骨髓供者4U 血分离的白细胞层(未经放射处理)。最初14侧用氨甲喋呤预防移植物抗宿主病(GVHD),以后4例则改用环孢菌素 A。
The authors report 53 patients with severe aplastic anemia (aplastic anemia), of which 3 were late at admission and died without specific treatment. The remaining 50 cases were divided into 3 groups. The age, etiology, previous treatment, blood and blood transfusion history in the 3 groups were similar. Group A: In 18 cases, the same sibling bone marrow of HLA-A, B, Dr was entered into the mixed lymphocyte culture without reaction. The average input 3.75 × 10 ~ 3 bone marrow nucleated cells / kg. Four weeks before the administration of cyclophosphamide, each 50mg / kg. Seven patients had a major ABO barrier requiring replacement of plasma. The first seven cases were given bone marrow only, and the remaining 11 cases were infused with a white blood cell layer separated from the 4U blood of the bone marrow donor (without radiation treatment) every day five days after the bone marrow transplantation. The first 14 sides methotrexate to prevent graft versus host disease (GVHD), after 4 cases instead of cyclosporine A.